Who is sponsoring NCT05860439?

NCT05860439 is sponsored by UPECLIN HC FM Botucatu Unesp.

What drugs are being tested in NCT05860439?

Interventions in NCT05860439: Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG).

What condition does NCT05860439 study?

NCT05860439 studies Telangiectasis.

Is NCT05860439 still recruiting?

NCT05860439 is currently completed. Last updated 18 October 2023.

Last reviewed 2023-10-18 · How we verify

NCT05860439

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias

Completed Last updated 18 October 2023

What this trial tests

trial testing Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG) in Telangiectasis in 191 participants. Completed in 1 June 2023.

Timeline

1 January 2017

Primary endpoint
1 May 2023

1 June 2023

Quick facts

Lead sponsor	UPECLIN HC FM Botucatu Unesp
Status	Completed
Study type	OBSERVATIONAL
Enrollment	191
Start date	1 January 2017
Primary completion	1 May 2023
Estimated completion	1 June 2023
Sites	1 location across Brazil

Drugs / interventions tested

Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)

Conditions studied

Telangiectasis — all drugs for Telangiectasis →

Sponsor

UPECLIN HC FM Botucatu Unesp — full company profile →

Who can join

Adults 18 to 90, female only, with Telangiectasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A long-term follow-up cohort study of patients that were assigned in two previous studies to compare the clinical results of sclerotherapy of telangiectasias and reticular veins of lower limbs using 0.2% polidocanol diluted in 70% hypertonic glucose (PDHG) vs 75% hypertonic glucose (HG) alone. All women, previously treated as aforementioned, were invited to be reevaluated regarding late maintenance and pigmentation over two years of follow-up. No new treatments were applied to the cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other UPECLIN HC FM Botucatu Unesp trials

Trials by the same sponsor.

NCT06326203 — Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia · Phase 1, PHASE2 · not yet recruiting
NCT06673225 — INSPIRE Respiratory Health Program in Botucatu, São Paulo, Brazil · recruiting
NCT06214429 — Shear Wave Elastography for Carotid Atherosclerotic Plaques · recruiting
NCT04937543 — Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 · Phase 2 · completed
NCT04743011 — Enriched Heparin Anti COVID-19 Trial · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05860439 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UPECLIN HC FM Botucatu Unesp
Last refreshed: 18 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05860439.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing